Related Experiment Video
Updated: May 15, 2025
11:36
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
Published on: April 28, 2016
8.5K
Incretin mimetics for weight loss forgive nonadherence
Anıl Cengiz1, Calvin C Wu2, Sean D Lawley1
1Department of Mathematics, University of Utah, Salt Lake City, Utah, USA.
Diabetes, Obesity & Metabolism
|May 14, 2025
Summary
Weight loss drugs like GLP-1 agonists are effective even with missed doses. Studies show significant weight loss is still possible even if patients take only half of their prescribed incretin mimetic doses.
Area of Science:
- Pharmacology and Endocrinology
- Obesity Medicine
- Mathematical Modeling in Medicine
Background:
- Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)-GLP-1 agonists are potent weight-loss medications.
- Low patient adherence is a common challenge with incretin mimetics, potentially limiting clinical efficacy.
- Defining "adequate" adherence is crucial for maximizing treatment outcomes.
Purpose of the Study:
- To investigate the impact of imperfect adherence on the weight loss efficacy of incretin mimetics.
- To determine the threshold of adherence required for clinically meaningful weight loss with these agents.
Main Methods:
- Utilized mathematical modeling and stochastic simulation to analyze weight loss efficacy under nonadherent conditions.
- Employed validated pharmacokinetic and pharmacodynamic models for semaglutide and tirzepatide.
- Simulated patient adherence by randomly omitting doses.
Main Results:
- Semaglutide and tirzepatide demonstrate forgiveness of nonadherence, maintaining significant weight loss efficacy despite missed doses.
- Achieving 80% adherence results in approximately 90% of the weight loss seen with perfect adherence.
- Even 50% adherence yields nearly 70% of the weight loss achieved under perfect adherence, with minimal weight fluctuations.
Conclusions:
- Incretin mimetics are highly effective for obesity management, even with suboptimal adherence.
- The traditional requirement of 80% adherence for significant weight loss may need re-evaluation for these medications.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
270
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
270
01:23Dipeptidyl Peptidase 4 Inhibitors
136
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
136
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
125
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
125
01:06Oral Hypoglycemic Agents: Glinides
111
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
111
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
141
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
141
01:30Regulation of Food Intake
150
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
150